A

Amerisourcebergen Corp
LSE:0HF3

Watchlist Manager
Amerisourcebergen Corp
LSE:0HF3
Watchlist
Price: 249.24 USD -0.59% Market Closed
Market Cap: 51.7B USD
Have any thoughts about
Amerisourcebergen Corp?
Write Note

Gross Margin
Amerisourcebergen Corp

3.3%
Current
3%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
3.3%
=
Gross Profit
9.8B
/
Revenue
294B

Gross Margin Across Competitors

Country US
Market Cap 48.9B USD
Gross Margin
3%
Country US
Market Cap 77.7B USD
Gross Margin
4%
Country US
Market Cap 48.4B USD
Gross Margin
3%
Country US
Market Cap 30.1B USD
Gross Margin
3%
Country US
Market Cap 9.3B USD
Gross Margin
32%
Country CN
Market Cap 65B CNY
Gross Margin
32%
Country KR
Market Cap 12.2T KRW
Gross Margin
30%
Country CN
Market Cap 65.4B HKD
Gross Margin
8%
Country CN
Market Cap 60.9B CNY
Gross Margin
11%
Country IT
Market Cap 5.5B EUR
Gross Margin
24%
Country DE
Market Cap 5B EUR
Gross Margin
10%
No Stocks Found

Amerisourcebergen Corp
Glance View

Market Cap
48.6B USD
Industry
Health Care
Economic Moat
None

AmerisourceBergen Corp. is a leading healthcare services company that plays an essential role in the pharmaceutical supply chain, connecting manufacturers, healthcare providers, and patients. Founded in 2001 and headquartered in Chesterbrook, Pennsylvania, the company has grown through strategic acquisitions and an unwavering commitment to improving patient access to critical medications. AmerisourceBergen stands out by providing a wide range of services, including drug distribution, specialty pharmacy solutions, and healthcare consulting, making it a vital partner for thousands of healthcare organizations across the United States and beyond. By prioritizing innovation and efficiency, they not only streamline pharmaceutical delivery but also enhance patient care in an increasingly complex healthcare landscape. As investors consider AmerisourceBergen, they can take comfort in the company’s impressive financial performance and resilience against market fluctuations. With a robust revenue stream primarily generated from the distribution of pharmaceuticals, AmerisourceBergen benefits from the growing demand for healthcare products and services. Additionally, the company's strategic partnerships and investment in technology position it well for future growth, particularly in the specialty drug sector, which is expanding rapidly due to the rise of biologics and personalized medicine. AmerisourceBergen's focus on operational excellence and customer satisfaction not only fosters loyalty among its clients but also supports a stable and attractive investment outlook, making it a compelling option for those looking to capitalize on the evolving healthcare market.

0HF3 Intrinsic Value
454.17 USD
Undervaluation 45%
Intrinsic Value
Price
A

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
3.3%
=
Gross Profit
9.8B
/
Revenue
294B
What is the Gross Margin of Amerisourcebergen Corp?

Based on Amerisourcebergen Corp's most recent financial statements, the company has Gross Margin of 3.3%.